Bilastine for the treatment of urticaria

Bibliography

• Zuberbier T, Maurer M. Urticaria: current opinions about etiology, diagnosis and therapy. Acta Derm Venereol 2007;87:196-205
   PubMed Web of Science ®Google Scholar
• Magerl M, Borzova E, Gimenez-Arnau A, et al. The definition and diagnostic testing of physical and cholinergic urticarias – EAACI/GA2LEN/EDF/UNEV consensus panel recommendations. Allergy 2009;64:1715-21
   PubMed Web of Science ®Google Scholar
• Ferrer M, Kaplan AP. Progress and challenges in the understanding of chronic urticaria. Allergy Asthma Clin Immunol 2007;3:31-5
   PubMedGoogle Scholar
• Leznoff A, Sussman GL. Syndrome of idiopathic chronic urticaria and angioedema with thyroid autoimmunity: a study of 90 patients. J Allergy Clin Immunol 1989;84(1):66-7
   PubMed Web of Science ®Google Scholar
• Maurer M, Ortonne JP, Zuberbier T. Chronic urticaria: an internet survey of health behaviours, symptom patterns and treatment needs in European adult patients. Br J Dermatol 2009;160:633-41
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy 2009;64:1427-43
   PubMed Web of Science ®Google Scholar
• Ferrer M, Sastre J, Jáuregui I, et al. Effect of antihistamine dose escalation in chronic urticaria. J Investig Allergol Clin Immunol 2011;21(Suppl 3):34-9
   PubMed Web of Science ®Google Scholar
• Church MK. Comparative inhibition by bilastine and cetirizine of histamine induced wheal and flare responses in humans. Inflamm Res 2011;60(12):1107-12
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Oanta A, Bogacka E, et al. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria: a multi-centre, double-blind, randomized, placebo-controlled study. Allergy 2010;65(4):516-28
   PubMed Web of Science ®Google Scholar
• Scaglione F. Safety profile of Bilastine: 2nd generation h1-antihistamines. Eur Rev Med Pharmacol Sci 2012;16:1999-2005
   PubMed Web of Science ®Google Scholar
• Church MK, Maurer M, Simons FE, et al. Global Allergy and Asthma European Network. Risk of first-generation H1-antihistamines: a GA(2)LEN position paper. Allergy 2010;65(4):459-66
   PubMed Web of Science ®Google Scholar
• Simons FER, Simons KJ. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol 2011;128:1139-50
   PubMed Web of Science ®Google Scholar
• Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA(2)LEN task force report. Allergy 2011;66:317-30
   PubMed Web of Science ®Google Scholar
• Ferrer E, Pandian R, Bolós J, et al. Bilastine. Drugs Future 2010;35(2):98-105
   Google Scholar
• Holgate ST, Canonica GW, Simons FER, et al. Consensus group on new generation antihistamines (CONGA): present status and recommendations. Clin Exp Allergy 2003;33:1305-24
   PubMed Web of Science ®Google Scholar
• Corcóstegui R, Labeaga L, Innerarity A, et al. Preclinical pharmacology of bilastine, a new selective histamine H1 receptor antagonist.receptor selectivity and in vitro antihistaminic activity. Drugs RD 2005;6(6):371-84
   PubMedGoogle Scholar
• Corcóstegui R, Labeaga L, Innerarity A, et al. In vivo pharmacological characterisation of bilastine, a potent and selective histamine H1 receptor antagonist. Drugs RD 2006;7(4):219-31
   PubMedGoogle Scholar
• Alvarez-Mon M, San Antonio E, Lucero M, et al. Bilastine, a novel antihistamine that preferentially inhibits histamine and interleukin-4 release from human mast cells and granulocytes [Abstract]. Allergy 2009;64(Suppl 90):555
   Google Scholar
• Jauregizar N, de la Fuente L, Lucero ML, et al. Pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effect of bilastine. Clin Pharmacokinet 2009;48(8):543-54
   PubMed Web of Science ®Google Scholar
• Sologuren A, Lucero ML, Valiente R, et al. Human mass balance with [14C. bilastine following oral administration to healthy volunteers. Basic Clin Pharmacol Toxicol 2009;105(Suppl 1):abstract TP85
   Google Scholar
• Crean C, Valiente R, Sologuren A, et al. Effect of grapefruit juice on the pharmacokinetics of bilastine. J Clin Pharmacol 2007;47(9):abstract 71
   Google Scholar
• Bailey DG. Fruit juice inhibition of uptake transport: a new type of food-drug interaction. Br J Clin Pharmacol 2010;70:645-55
   PubMed Web of Science ®Google Scholar
• Crean C, Sologuren A, Valiente R, et al. The drug-drug interaction of ketoconazole on bilastine pharmacokinetics. Basic Clin Pharmacol Toxicol 2007;101(Suppl 1):abstract P253
   Google Scholar
• Bachert C, Kuna P, Zuberbier T. Bilastine in allergic rhinoconjunctivitis and urticaria. Allergy 2010;65(Suppl 93):1-13
   Web of Science ®Google Scholar
• Audicana MT, Lecha M, Marquina A, et al. Adouble-blind, randomized, dose-ranging trial in four parallel groups of 10, 20 and 30 mg bilastine once daily vs placebo in the symptomatic treatment of chronic idiopathic urticaria (CIU). J Investig Allergol Clin Immunol 2007;17(Suppl 3):77
   PubMedGoogle Scholar
• Młynek A, Zalewska-Janowska A, Martus P, et al. How to assess disease activity in patients with chronic urticaria? Allergy 2008;63:777-80
   PubMed Web of Science ®Google Scholar
• Sadaba B, Azanza JR, Gomez-Guiu A. Bilastine for the relief of allergy symptoms. Drugs of Today 2011;47(4):251-62
   PubMedGoogle Scholar
• Krause K, Spohr A, Church MK, et al. High-dose bilastine is effective in reducing temperature thresholds in cold contact urticaria. 2012 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI). Anaheim, CA (USA) Nov. 8-13, 2012 [abstract 62]. Ann Allergy Asthma Immunol 2012;10(Suppl 5):A37
   Google Scholar
• Montoro J, Sastre J, Bartra J, et al. Effect of H1 antihistamines upon the central nervous system. J Investig Allergol Clin Immunol 2006;16(Suppl 1):24-8
   PubMedGoogle Scholar
• Montoro J, Mullol J, Dávila IJ, et al. Bilastine and the central nervous system. J Investig Allergol Clin Immunol 2011;21(Suppl 3):9-15
   PubMed Web of Science ®Google Scholar
• Garcia-Gea C, Martinez-Colomer J, Antonijoan RM, et al. Comparison of peripheral and central effects of single and repeated oral dose administrations of bilastine, a new H1 antihistamine: a dose-range study in healthy volunteers with hydroxyzine and placebo as control treatments. J Clin Psychopharmacol 2008;28(6):675-85
   PubMed Web of Science ®Google Scholar
• Conen S, Theunissen EL, Van Oers AC, et al. Acute and subchronic effects of bilastine (20 and 40 mg) and hydroxyzine (50 mg) on actual driving performance in healthy volunteers. J Psychopharmacol 2011;25(11):1527-33
   Google Scholar
• Davila I, Sastre J, Bartra J, et al. Effect of H1- antihistamines upon the cardiovascular system. J Investig Allergol Clin Immunol 2006;16(Suppl 1):13-23
   PubMedGoogle Scholar
• Taglialatela M, Pannaccione A, Castaldo P, et al. Molecular basis for the lack of HERG K+ channel block-related cardiotoxicity by the H1 receptor blocker cetirizine compared with other second-generation antihistamines. Mol Pharmacol 1998;54:113-21
   PubMed Web of Science ®Google Scholar
• Tyl B, Kabbaj M, Azzam S, et al. Lack of significant effect of bilastine administered at therapeutic and supratherapeutic doses and concomitantly with ketoconazole on ventricular repolarization: results of a thorough QT study (TQTS) with QT concentration analysis. J Clin Pharmacol 2012;52(6):893-903
   PubMed Web of Science ®Google Scholar
• Bachert C, Kuna P, Sanquer F, et al. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy 2009;64(1):158-65
   PubMed Web of Science ®Google Scholar
• Kuna P, Bachert C, Nowacki Z, Bilastine International Working Group. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clin Exp Allergy 2009;39(9):1338-47
   PubMed Web of Science ®Google Scholar
• Sastre J, Mullol J, Valero A, Valiente R; on behalf of Bilastine Study Group. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo in the treatment of perennial allergic rhinitis. Curr Med Res Opin 2012;28(1):121-30
   PubMed Web of Science ®Google Scholar